The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Attenuation of long-term survival benefit of biological therapy in metastatic colorectal cancer (mCRC): Real-world data validation and molecular characterization.
 
Sanjay Goel
No Relationships to Disclose
 
Yasmine Baca
Employment - Caris Life Sciences
Stock and Other Ownership Interests - Caris Life Sciences
 
Joanne Xiu
No Relationships to Disclose
 
Heinz-Josef Lenz
Honoraria - Abbvie; Adagene; Bayer; Boehringer Ingelheim; Fulgent Genetics; Janssen Oncology; Jazz Pharmaceuticals; Merck Serono; Merus; Roche
Consulting or Advisory Role - 3T BioSciences; Abbvie; Adagene; Bayer; BMS; Fulgent Genetics; GlaxoSmithKline; Merck Serono; Roche
Travel, Accommodations, Expenses - Bayer; BMS; Merck Serono
 
Rachna Shroff
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Boston Scientific; Ipsen; Novocure
Research Funding - Actuate Therapeutics; Arcus Biosciences; Compass Therapeutics; Exelixis; Fujifilm; Lisata; Loxo/Lilly; Merck; NGM Biopharmaceuticals; Novocure
 
Emil Lou
Stock and Other Ownership Interests - Ryght
Honoraria - Boston Scientific; Colorectal Cancer Alliance; Daiichi Sankyo/UCB Japan (Inst); GlaxoSmithKline; Novocure
Consulting or Advisory Role - Boston Scientific; Novocure; Novocure; Novocure; Novocure
Research Funding - Intima; Novocure
Travel, Accommodations, Expenses - GlaxoSmithKline
(OPTIONAL) Uncompensated Relationships - Caris Life Sciences; Minnetronix Medical; NomoCan
 
Anthony Shields
Consulting or Advisory Role - Caris Life Sciences; Cogent Biosciences; ImaginAb; Legend Biotech
Speakers' Bureau - Caris Life Sciences
Research Funding - Abbisko Therapeutics (Inst); Alkermes (Inst); Amal Therapeutics (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Biohaven Pharmaceuticals (Inst); Boehringer Ingelheim (Inst); Boston Biomedical (Inst); Caris Life Sciences (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Esperas Pharma (Inst); Esperas Pharma (Inst); Exelixis (Inst); Five Prime Therapeutics (Inst); Fusion Pharmaceuticals (Inst); Gritstone Bio (Inst); H3 Biomedicine (Inst); Halozyme (Inst); Hutchison China Meditech (Inst); IconOVir Bio (Inst); ImaginAb (Inst); Incyte (Inst); Inovio Pharmaceuticals (Inst); Jiangsu Alphamab Biopharmaceuticals (Inst); Lexicon (Inst); Lilly (Inst); LSK BioPharma (Inst); MSK Pharma (Inst); Nouscom (Inst); Novartis (Inst); Nuvation Bio (Inst); Perspective Therapeutics (Inst); Plexxikon (Inst); Repertoire Immune Medicines (Inst); Seagen (Inst); Shanghai HaiHe Pharmaceutical (Inst); Sorrento Therapeutics (Inst); SQZ Biotechnology (Inst); Taiho Pharmaceutical (Inst); Telix Pharmaceuticals (Inst); TheraBionic (Inst); TopAlliance BioSciences Inc (Inst); Torque (Inst); Xencor (Inst)
Travel, Accommodations, Expenses - Caris Life Sciences; GE Healthcare; ImaginAb; Inovio Pharmaceuticals; TransTarget
 
Moh'd Khushman
Stock and Other Ownership Interests - Cardiff Oncology; Moderna Therapeutics
Consulting or Advisory Role - Abbvie; bristol-myers squibb; Cardinal Health; Elevar Therapeutics; Exelixis; Guardant Health; Merus NV
Research Funding - Abbvie (Inst); BeiGene (Inst); FOGPharma (Inst); GlaxoSmithKline (Inst); IgM Biosciences (Inst); Merus NV (Inst); Torl Biotherapeutics (Inst)